The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19)
Open accessAbstract
As the coronavirus disease 19 (COVID-19) global pandemic rages across the globe, the race to prevent and treat this deadly disease has led to the “off-label” repurposing of drugs such as hydroxychloroquine and lopinavir/ritonavir, which have the potential for unwanted QT-interval prolongation and a risk of drug-induced sudden cardiac death. With the possibility that a considerable proportion of the world’s population soon could receive COVID-19 pharmacotherapies with torsadogenic potential for therapy or postexposure prophylaxis, this document serves to help health care professionals mitigate the risk of drug-induced ventricular arrhythmias while minimizing risk of COVID-19 exposure to personnel and conserving the limited supply of personal protective equipment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105949 · Cited by 5,288
RetractedClinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187
Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L., Dong, E., Song, C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa237 · Cited by 2,662
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Vincent, M. J., Bergeron, E., Benjannet, S., Erickson, B. R., Rollin, P. E., Ksiazek, T. G., Seidah, N. G., & Nichol, S. T. (2005) · Virology Journal · doi:10.1186/1743-422x-2-69 · Cited by 1,811
Effects of chloroquine on viral infections: an old drug against today's diseases
Savarino, A., Boelaert, J. R., Cassone, A., Majori, G., & Cauda, R. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00806-5 · Cited by 1,268
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Colson, P., Rolain, J.-M., Lagier, J.-C., Brouqui, P., & Raoult, D. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105932 · Cited by 937 · cited 1×
“5, 6 In light of (1) the need for this practice to continue in the absence of viable, evidence-based therapies and (2) the proclivity of many promising COVID-19 pharmacotherapiesdspecifically antimalarial agents such as hydroxychloroquinedto prolong the QTc, thereby increasing the risk of drug-induced torsades de poin…”
International Recommendations for Electrocardiographic Interpretation in Athletes
Sharma, S., Drezner, J. A., Baggish, A., Papadakis, M., Wilson, M. G., Prutkin, J. M., La Gerche, A., Ackerman, M. J., Borjesson, M., Salerno, J. C., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.01.015 · Cited by 598
Self-citationIn vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds
Chen, F., Chan, K. H., Jiang, Y., Kao, R. Y. T., Lu, H. T., Fan, K. W., Cheng, V. C. C., Tsui, W. H. W., Hung, I. F. N., & Lee, T. S. W. (2004) · Journal of Clinical Virology · doi:10.1016/j.jcv.2004.03.003 · Cited by 534
Cited by
The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030
Vogel, B., Acevedo, M., Appelman, Y., Bairey Merz, C. N., Chieffo, A., Figtree, G. A., Guerrero, M., Kunadian, V., Lam, C. S. P., Maas, A. H. E. M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00684-x · Cited by 1,488
Impact of sex and gender on COVID-19 outcomes in Europe
Gebhard, C., Regitz-Zagrosek, V., Neuhauser, H. K., Morgan, R., & Klein, S. L. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00304-9 · Cited by 1,306
Mehra, M. R., Desai, S. S., Ruschitzka, F., & Patel, A. N. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31180-6 · Cited by 1,200
RetractedConsiderations for Drug Interactions on QTc in Exploratory COVID-19 Treatment
Roden, D. M., Harrington, R. A., Poppas, A., & Russo, A. M. (2020) · Circulation · doi:10.1161/circulationaha.120.047521 · Cited by 779
Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome
Hendren, N. S., Drazner, M. H., Bozkurt, B., & Cooper, L. T. (2020) · Circulation · doi:10.1161/circulationaha.120.047349 · Cited by 576
Mahévas, M., Tran, V.-T., Roumier, M., Chabrol, A., Paule, R., Guillaud, C., Fois, E., Lepeule, R., Szwebel, T.-A., Lescure, F.-X., et al. (2020) · BMJ · doi:10.1136/bmj.m1844 · Cited by 566
Organ-specific manifestations of COVID-19 infection
Gavriatopoulou, M., Korompoki, E., Fotiou, D., Ntanasis-Stathopoulos, I., Psaltopoulou, T., Kastritis, E., Terpos, E., & Dimopoulos, M. A. (2020) · Clinical and Experimental Medicine · doi:10.1007/s10238-020-00648-x · Cited by 502
The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin
Chorin, E., Dai, M., Shulman, E., Wadhwani, L., Bar-Cohen, R., Barbhaiya, C., Aizer, A., Holmes, D., Bernstein, S., Spinelli, M., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0888-2 · Cited by 417
Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association
Tisdale, J. E., Chung, M. K., Campbell, K. B., Hammadah, M., Joglar, J. A., Leclerc, J., Rajagopalan, B., & On behalf of the American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing (2020) · Circulation · doi:10.1161/cir.0000000000000905 · Cited by 399
Joyner, M. J., Bruno, K. A., Klassen, S. A., Kunze, K. L., Johnson, P. W., Lesser, E. R., Wiggins, C. C., Senefeld, J. W., Klompas, A. M., Hodge, D. O., et al. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.06.028 · Cited by 398
Chorin, E., Wadhwani, L., Magnani, S., Dai, M., Shulman, E., Nadeau-Routhier, C., Knotts, R., Bar-Cohen, R., Kogan, E., Barbhaiya, C., et al. (2020) · Heart Rhythm · doi:10.1016/j.hrthm.2020.05.014 · Cited by 295
Wearable Sensing and Telehealth Technology with Potential Applications in the Coronavirus Pandemic
Ding, X., Clifton, D., Ji, N., Lovell, N. H., Bonato, P., Chen, W., Yu, X., Xue, Z., Xiang, T., Long, X., et al. (2021) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2020.2992838 · Cited by 281
Pharmaco-Immunomodulatory Therapy in COVID-19
Rizk, J. G., Kalantar-Zadeh, K., Mehra, M. R., Lavie, C. J., Rizk, Y., & Forthal, D. N. (2020) · Drugs · doi:10.1007/s40265-020-01367-z · Cited by 288
Lakkireddy, D. R., Chung, M. K., Gopinathannair, R., Patton, K. K., Gluckman, T. J., Turagam, M., Cheung, J. W., Patel, P., Sotomonte, J., Lampert, R., et al. (2020) · Heart Rhythm · doi:10.1016/j.hrthm.2020.03.028 · Cited by 259
Self-citationCegolon, L., Javanbakht, M., & Mastrangelo, G. (2020) · International Journal of Hygiene and Environmental Health · doi:10.1016/j.ijheh.2020.113605 · Cited by 44
New FDA guidance on general clinical trial conduct in the era of COVID-19
Turner, J. R. (2020) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-020-00160-0 · Cited by 20
Metadata
- Authors
- Giudicessi, J. R., Noseworthy, P. A., Friedman, P. A., & Ackerman, M. J.
- Venue
- Mayo Clinic Proceedings
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 95
- Issue
- 6
- Pages
- 1213-1221
- ISSN
- 0025-6196 (ISSN-L)
- OpenAlex
- W3015907249
- Cited by
- 394
- References
- 26
- FWCI
- 52.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.